Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Vor Biopharma Inc. is active in the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action currently under review. This workload is handled by 1 distinct examiner, showing that the number of pending office actions corresponds to the number of examiners involved in the company's prosecution. This concentration of work indicates that the company's current patent office interaction is limited to this specific matter.
The prosecution activity is situated within 1 distinct art unit. BUTTICE, AUDREY L is the busiest examiner for the company and is currently overseeing 1 pending office action. Because the total number of pending actions is 1, BUTTICE, AUDREY L is responsible for all of the company's current examiner-level engagement. This means the outcome of the portfolio's current prosecution depends on the decisions of this individual within the specified art unit. Practitioners must account for the specific technical review of BUTTICE, AUDREY L in the biotech sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUTTICE, AUDREY L | 1 | 47.9% | +25.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18269633 | COMPOSITIONS AND METHODS FOR CD34 GENE MODIFICATION | BUTTICE, AUDREY L | 76d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18269633 | COMPOSITIONS AND METHODS FOR CD34 GENE MODIFICATION | BUTTICE, AUDREY L | 76d |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18269633 | COMPOSITIONS AND METHODS FOR CD34 GENE MODIFICATION | BUTTICE, AUDREY L | 1647 | §103§112 | Non-Final OA | 76d | Pending | Jun 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial